Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma

Br J Haematol. 2014 Oct;167(1):141-4. doi: 10.1111/bjh.12944. Epub 2014 May 29.
No abstract available

Keywords: cutaneous T cell lymphoma; peripheral T cell lymphoma; salvage therapy; sorafenib; tyrosine kinase inhibitor.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology*
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / pathology*
  • Neoplasm Recurrence, Local
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Pilot Projects
  • Protein Kinase Inhibitors / therapeutic use*
  • Sorafenib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Niacinamide
  • Sorafenib